Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7777 and Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT05200559Phase 2Active, not recruiting
- Start
- Sep 2022
- Primary completion
- May 2030
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of denileukin diftitox in solid tumor, ovarian cancer. Started Sep 2022; status: active, not recruiting.
02
Drugs
denileukin diftitox
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT05200559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200559.